Financials data is unavailable for this security.
View more
Year on year BRAIN Biotech AG had net income fall 25.63% from a loss of 6.59m to a larger loss of 8.28m despite a 11.79% increase in revenues from 50.30m to 56.23m. An increase in the cost of goods sold as a percentage of sales from 43.87% to 44.84% was a component in the falling net income despite rising revenues.
| Gross margin | 56.66% |
|---|---|
| Net profit margin | -15.71% |
| Operating margin | -10.53% |
| Return on assets | -12.31% |
|---|---|
| Return on equity | -44.22% |
| Return on investment | -15.45% |
More ▼
Cash flow in EURView more
In 2023, cash reserves at BRAIN Biotech AG fell by 3.09m. However, Cash Flow from Investing totalled 562.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 4.22m for operations while cash generated from financing totalled 459.00k.
| Cash flow per share | -0.184 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.7486 |
|---|---|
| Tangible book value per share | 0.7486 |
More ▼
Balance sheet in EURView more
| Current ratio | 2.57 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
